Laboratorios Richmond S.A.C.I.F. (BCBA:RICH)

Market Cap	134.85B -0.9%
Revenue (ttm)	126.73B +4.9%
Net Income	3.09B -90.2%
EPS	38.24 -90.2%
Shares Out	80.75M
PE Ratio	56.09
Forward PE	n/a
Dividend	26.89 (1.61%)
Ex-Dividend Date	n/a

Volume	4,202
Average Volume	6,226
Open	1,690.00
Previous Close	1,715.00
Day's Range	1,635.00 - 1,715.00
52-Week Range	945.00 - 2,300.00
Beta	-0.55
RSI	45.18
Earnings Date	May 7, 2026

About BCBA:RICH

Laboratorios Richmond S.A.C.I.F., together with its subsidiaries, develops, manufactures, and sells pharmaceutical products in Latin America, Africa, Asia, and the Middle East. It offers antiretroviral drugs for the treatment of human immunodeficiency virus; oncology and oncohematology drugs; cardiometabolism drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs, such as analgesics, antipsychotics, antidepressants, anti-dementia, antiepileptics, and hypnot...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 620
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: RICH

Financial Performance

In 2025, BCBA:RICH's revenue was 126.73 billion, an increase of 4.95% compared to the previous year's 120.75 billion. Earnings were 3.09 billion, a decrease of -90.16%.